Evidence map›Paper›PMID 40405004›Full record

ArticleClinical and experimental medicine2025

Multidimensional integrated lung protection measures attenuate pulmonary inflammation and improve lung function by inhibiting the NF-κB signaling pathway in elderly patients with lung dysfunction.

Yan Zhang, Hao Li, Dan Yin, Mandi Wu, Yinghui Cui, Jinhuo Wang, Zhanyu Cheng, Yujia Wang, Huan Wang, Jianrong Guo

Abstract read
In one paragraph

Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yan Zhang *Postgraduate Training Base at Shanghai Gongli Hospital, Ningxia Medical University, Shanghai, 200135, China.
Hao Li *Postgraduate Training Base at Shanghai Gongli Hospital, Ningxia Medical University, Shanghai, 200135, China.
Dan Yin *Department of Anesthesiology, Gongli Hospital of Shanghai Pudong New Area, No. 219, Miaopu Road, Pudong New Area, Shanghai, 200135, People's Republic of China.
Mandi WuDepartment of Anesthesiology, Gongli Hospital of Shanghai Pudong New Area, No. 219, Miaopu Road, Pudong New Area, Shanghai, 200135, People's Republic of China.
Yinghui CuiDepartment of Anesthesiology, Gongli Hospital of Shanghai Pudong New Area, No. 219, Miaopu Road, Pudong New Area, Shanghai, 200135, People's Republic of China.
Jinhuo WangDepartment of Anesthesiology, Gongli Hospital of Shanghai Pudong New Area, No. 219, Miaopu Road, Pudong New Area, Shanghai, 200135, People's Republic of China.
Zhanyu ChengDepartment of Anesthesiology, Gongli Hospital of Shanghai Pudong New Area, No. 219, Miaopu Road, Pudong New Area, Shanghai, 200135, People's Republic of China.
Yujia WangDepartment of Anesthesiology, Gongli Hospital of Shanghai Pudong New Area, No. 219, Miaopu Road, Pudong New Area, Shanghai, 200135, People's Republic of China.
Huan WangDepartment of Anesthesiology, Gongli Hospital of Shanghai Pudong New Area, No. 219, Miaopu Road, Pudong New Area, Shanghai, 200135, People's Republic of China. cheerybaby2015@163.com.
Jianrong GuoDepartment of Anesthesiology, Gongli Hospital of Shanghai Pudong New Area, No. 219, Miaopu Road, Pudong New Area, Shanghai, 200135, People's Republic of China. gjr_2024@126.com.

Funding

Joint research project of Shanghai Pudong New Area Health Commission PW2022D-02Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai PWZxq2022-5
6 · The paper itself

Abstract

Elderly patients with lung dysfunction (EPLD) often experience chronic inflammation and impaired immune responses, significantly impacting their health outcomes. Currently, no specific treatment exists to prevent lung dysfunction in elderly patients. The detailed mechanism of lung dysfunction in elderly patients remains elusive, and this study aims to clarify it. General data and blood specimens were obtained from EPLD. A lung dysfunction mouse model was established by anesthetizing and ventilating BALB/c mice at a high tidal volume of 30 mL/kg. Blood samples and lung tissues were collected from all groups for further testing. HE staining, immunofluorescence, Western blot, ELISA, flow cytometry, and qRT-PCR were used to elucidate the molecular mechanisms of multidimensional integrated lung protection measures (MILPM) in lung dysfunction mice by targeting the NF-κB pathway. The results indicated that upregulation of the NF-κB signaling pathway accelerates the lung dysfunction process, while downregulation of the NF-κB signaling pathway can prevent it. Similarly, the upregulation of TNF-α, IL-6, IL-1β, and ROS levels is associated with the lung dysfunction process, whereas reducing their levels can serve as a preventative method against lung dysfunction development. Upregulation of the NF-κB pathway can accelerate the process of lung dysfunction.

Indexed as

LungNF-kappa BPneumoniaSignal TransductionAgedAnimalsCytokinesDisease Models, AnimalFemaleHumansMaleMiceMice, Inbred BALB CCytokinesNF-kappa BElderly patients with lung dysfunctionMultidimensional integrated lung protection measuresNF-κB pathway

Identifiers

PMID40405004
PMCPMC12098184

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.